A Novel Peptide, HS1002, Enhances Antitumor Activity via Dual Targeting of the GnRH Receptor and Human Telomerase Reverse Transcriptase in Prostate Cancer Cells

Abstract

Human telomerase reverse transcriptase (hTERT) is overexpressed in most human cancers and is an important target for cancer therapy. In this study, HS1002 was synthesized based on the amino acid sequences of gonadotropin-releasing hormone (GnRH) and hTERT. This study aimed to evaluate HS1002's anticancer activity and its effects on the gonadotropin-releasing hormone receptor (GnRHR) and hTERT in prostate cancer cells. HS1002 increased cytosolic calcium influx in GnRHR-overexpressing HEK293 cells and showed specific molecular docking interactions with GnRHR. Compared with prostate cancer cell lines, HS1002 exhibited the highest cytotoxicity against LNCaP cells. The hTERT expression correlated with telomerase activity was suppressed by HS1002, resulting in reduced metastasis and increased apoptosis and autophagy. Additionally, HS1002 suppressed c-Myc and ERK protein expressions in LNCaP cells. Furthermore, HS1002 inhibited tumor growth and downregulated hTERT expression in the xenograft model tumor tissues. HS1002/IL-2-pretreated PBMCs also exhibited potent cytotoxicity toward LNCaP cells. In addition, HS1002 increased the production of granzyme B and IFN-γ in CD8⁺ T cells in MC38 syngeneic mice. These findings demonstrate that HS1002 suppresses prostate cancer cell growth and induces anticancer immunity, suggesting its potential as a novel therapeutic agent against prostate cancer.

Keywords

GnRHR / HS1002 / hTERT / immune response / prostate cancer

References

[1] N. Srinivas, S. Rachakonda, and R. Kumar, “Telomeres and Telomere Length: A General Overview,” Cancers (Basel) 12, no. 3 (2020): 558.

[2] M. K. Graham and A. Meeker, “Telomeres and Telomerase in Prostate Cancer Development and Therapy,” Nature Reviews Urology 14, no. 10 (2017): 607–619.

[3] E. Ségal-Bendirdjian and V. Geli, “Non-Canonical Roles of Telomerase: Unraveling the Imbroglio,” Frontiers in Cell and Developmental Biology 7 (2019): 332.

[4] R. Leão, J. D. Apolónio, D. Lee, A. Figueiredo, U. Tabori, and P. Castelo-Branco, “Mechanisms of Human Telomerase Reverse Transcriptase (hTERT) Regulation: Clinical Impacts in Cancer,” Journal of Biomedical Science 25, no. 1 (2018): 22.

[5] M. Taheri, S. Ghafouri-Fard, S. Najafi, et al., “Hormonal Regulation of Telomerase Activity and hTERT Expression in Steroid-Regulated Tissues and Cancer,” Cancer Cell International 22, no. 1 (2022): 258.

[6] M. Garg, V. Singh, M. Kumar, and S. N. Sankhwar, “Hormonal Therapy in Metastatic Prostate Cancer: Current Perspectives and Controversies,” Oncology Reviews 7, no. 1 (2013): e6.

[7] Z. Naor, “Signaling by G-Protein-Coupled Receptor (GPCR): Studies on the GnRH Receptor,” Frontiers in Neuroendocrinology 30, no. 1 (2009): 10–29.

[8] C. Gründker and G. Emons, “The Role of Gonadotropin-Releasing Hormone in Cancer Cell Proliferation and Metastasis,” Frontiers in Endocrinology (Lausanne) 8 (2017): 187.

[9] E. B. Ellingsen, S. M. Mangsbo, E. Hovig, and G. Gaudernack, “Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential,” Frontiers in Immunology 12 (2021): 682492.

[10] E. M. Inderberg-Suso, S. Trachsel, K. Lislerud, A. M. Rasmussen, and G. Gaudernack, “Widespread CD4+ T-Cell Reactivity to Novel hTERT Epitopes Following Vaccination of Cancer Patients with a Single hTERT Peptide GV1001,” Oncoimmunology 1, no. 5 (2012): 670–686.

[11] J. W. Kim, D. K. Yadav, S. J. Kim, et al., “Anti-Cancer Effect of GV1001 for Prostate Cancer: Function as a Ligand of GnRHR,” Endocrine-Related Cancer 26, no. 2 (2019): 147–162.

[12] S. V. Moradi, P. Varamini, and I. Toth, “Evaluation of the Biological Properties and the Enzymatic Stability of Glycosylated Luteinizing Hormone-Releasing Hormone Analogs,” AAPS Journal 17, no. 5 (2015): 1135–1143.

[13] P. Singh and A. Krishna, “Effects of GnRH Agonist Treatment on Steroidogenesis and Folliculogenesis in the Ovary of Cyclic Mice,” Journal of Ovarian Research 3 (2010): 26.

[14] F. Labrie, A. Bélanger, V. Luu-The, et al., “Gonadotropin-Releasing Hormone Agonists in the Treatment of Prostate Cancer,” Endocrine Reviews 26, no. 3 (2005): 361–379.

[15] C. A. Flanagan and A. Manilall, “Gonadotropin-Releasing Hormone (GnRH) Receptor Structure and GnRH Binding,” Frontiers in Endocrinology (Lausanne) 8 (2017): 274.

[16] W. Yan, L. Cheng, W. Wang, et al., “Structure of the Human Gonadotropin-Releasing Hormone Receptor GnRH1R Reveals an Unusual Ligand Binding Mode,” Nature Communications 11, no. 1 (2020): 5287.

[17] L. Suo, X. Chang, N. Xu, and H. Ji, “The Anti-Proliferative Activity of GnRH through Downregulation of the Akt/ERK Pathways in Pancreatic Cancer,” Frontiers in Endocrinology (Lausanne) 10 (2019): 370.

[18] R. N. Wang, Q. Wen, W. T. He, et al., “Optimized Protocols for Γδ T Cell Expansion and Lentiviral Transduction,” Molecular Medicine Reports 19, no. 3 (2019): 1471–1480.

[19] P. Kokhaei, M. Palma, L. Hansson, A. Osterborg, H. Mellstedt, and A. Choudhury, “Telomerase (hTERT 611–626) Serves as a Tumor Antigen in B-Cell Chronic Lymphocytic Leukemia and Generates Spontaneously Antileukemic, Cytotoxic T Cells,” Experimental Hematology 35, no. 2 (2007): 297–304.

[20] J. M. Mazet, J. N. Mahale, O. Tong, et al., “IFNγ Signaling in Cytotoxic T Cells Restricts Anti-Tumor Responses by Inhibiting the Maintenance and Diversity of Intra-Tumoral Stem-Like T Cells,” Nature Communications 14, no. 1 (2023): 321.

[21] M. J. Karten and J. E. Rivier, “Gonadotropin-Releasing Hormone Analog Design. Structure-Function Studies toward the Development of Agonists and Antagonists: Rationale and Perspective,” Endocrine Reviews 7, no. 1 (1986): 44–66.

[22] R. Maggi, “Physiology of Gonadotropin-Releasing Hormone (GnRH): Beyond the Control of Reproductive Functions,” MOJ Anatomy and Physiology 2, no. 5 (2016): 150–154.

[23] R. P. Millar, Z. L. Lu, A. J. Pawson, C. A. Flanagan, K. Morgan, and S. R. Maudsley, “Gonadotropin-Releasing Hormone Receptors,” Endocrine Reviews 25, no. 2 (2004): 235–275.

[24] T. Liu, X. Liang, B. Li, M. Björkholm, J. Jia, and D. Xu, “Telomerase Reverse Transcriptase Inhibition Stimulates Cyclooxygenase 2 Expression in Cancer Cells and Synergizes with Celecoxib to Exert Anti-Cancer Effects,” British Journal of Cancer 108, no. 11 (2013): 2272–2280.

[25] N. Nagai, T. Oshita, K. Mukai, Y. Shiroyama, K. Shigemasa, and K. Ohama, “GnRH Agonist Inhibits Human Telomerase Reverse Transcriptase mRNA Expression in Endometrial Cancer Cells,” International Journal of Molecular Medicine 10, no. 5 (2002): 593–597.

[26] H. Ohta, H. Sakamoto, and K. Satoh, “In Vitro Effects of Gonadotropin-Releasing Hormone (GnRH) Analogue on Cancer Cell Sensitivity to Cis-Platinum,” Cancer Letters 134, no. 1 (1998): 111–118.

[27] Y. Deng, S. S. Chan, and S. Chang, “Telomere Dysfunction and Tumor Suppression: The Senescence Connection,” Nature Reviews Cancer 8, no. 6 (2008): 450–458.

[28] J. W. Moul and N. Dawson, “Quality of Life Associated with Treatment of Castration-Resistant Prostate Cancer: A Review of the Literature,” Cancer Investigation 30, no. 1 (2012): 1–12.

[29] Z. Yu, S. Chen, A. G. Sowalsky, et al., “Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer,” Clinical Cancer Research 20, no. 6 (2014): 1590–1600.

[30] P. Gu, X. Chen, R. Xie, et al., “LncRNA HOXD-AS1 Regulates Proliferation and Chemoresistance of Castration-Resistant Prostate Cancer via Recruiting WDR5,” Molecular Therapy 25, no. 8 (2017): 1959–1973.

[31] P. Gu, X. Chen, R. Xie, et al., “A Novel AR Translational Regulator lncRNA LBCS Inhibits Castration Resistance of Prostate Cancer,” Molecular Cancer 18, no. 1 (2019): 109.

[32] R. Bu, A. K. Siraj, S. P. Divya, et al., “Telomerase Reverse Transcriptase Mutations Are Independent Predictors of Disease-Free Survival in Middle Eastern Papillary Thyroid Cancer,” International Journal of Cancer 142, no. 10 (2018): 2028–2039.

[33] M. G. Dozmorov, R. E. Hurst, D. J. Culkin, et al., “Unique Patterns of Molecular Profiling between Human Prostate Cancer LNCaP and PC-3 Cells,” The Prostate 69, no. 10 (2009): 1077–1090.

[34] S. M. Dehm, L. J. Schmidt, H. V. Heemers, R. L. Vessella, and D. J. Tindall, “Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor That Mediates Prostate Cancer Therapy Resistance,” Cancer Research 68, no. 13 (2008): 5469–5477.

[35] S. Liu, Y. Qi, Y. Ge, et al., “Telomerase as an Important Target of Androgen Signaling Blockade for Prostate Cancer Treatment,” Molecular Cancer Therapeutics 9, no. 7 (2010): 2016–2025.

[36] C. Guo, B. N. Armbruster, D. T. Price, and C. M. Counter, “In Vivo Regulation of hTERT Expression and Telomerase Activity by Androgen,” Journal of Urology 170, no. 2 Pt 1 (2003): 615–618.

[37] J. W. Kim, M. Park, S. Kim, S. C. Lim, H. S. Kim, and K. W. Kang, “Anti-Metastatic Effect of GV1001 on Prostate Cancer Cells: Roles of GnRHR-Mediated Gαs–cAMP Pathway and AR–YAP1 Axis,” Cell and Bioscience 11, no. 1 (2021): 191.

[38] Q. Zhang, N. Liu, J. Bai, et al., “Human Telomerase Reverse Transcriptase Is a Novel Target of the Hippo–YAP Pathway,” FASEB Journal 34, no. 3 (2020): 4178–4188.

[39] E. V. Pappa, A. A. Zompra, Z. Spyranti, et al., “Enzymatic Stability, Solution Structure, and Antiproliferative Effect on Prostate Cancer Cells of Leuprolide and New Gonadotropin-Releasing Hormone Peptide Analogs,” Biopolymers 96, no. 3 (2011): 260–272.

[40] F. Fontana, M. Marzagalli, M. M. Marelli, et al., “Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions,” International Journal of Molecular Sciences 21, no. 24 (2020): 9511.

[41] S. Sperduti, S. Limoncella, C. Lazzaretti, et al., “GnRH Antagonists Produce Differential Modulation of the Signaling Pathways Mediated by GnRH Receptors,” International Journal of Molecular Sciences 20, no. 22 (2019): 5548.

[42] Y. He, W. Xu, Y. T. Xiao, H. Huang, D. Gu, and S. Ren, “Targeting Signaling Pathways in Prostate Cancer: Mechanisms and Clinical Trials,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 198.

[43] M. M. Jie, X. Chang, S. Zeng, et al., “Diverse Regulatory Manners of Human Telomerase Reverse Transcriptase,” Cell Communication and Signaling 17, no. 1 (2019): 63.

[44] C. M. Koh, C. J. Bieberich, C. V. Dang, W. G. Nelson, S. Yegnasubramanian, and A. M. De Marzo, “MYC and Prostate Cancer,” Genes and Cancer 1, no. 6 (2010): 617–628.

[45] K. J. Wu, C. Grandori, M. Amacker, et al., “Direct Activation of TERT Transcription by c-MYC,” Nature Genetics 21, no. 2 (1999): 220–224.

[46] X. Ren, Z. Zhang, J. Tian, et al., “The Downregulation of c-Myc and Its Target Gene hTERT Is Associated with the Antiproliferative Effects of Baicalin on HL-60 Cells,” Oncology Letters 14, no. 6 (2017): 6833–6840.

[47] F. Dogan and C. Biray Avci, “Correlation between Telomerase and mTOR Pathway in Cancer Stem Cells,” Gene 641 (2018): 235–239.

[48] C. Zhou, T. A. Steplowski, H. K. Dickens, et al., “Estrogen Induction of Telomerase Activity through Regulation of the Mitogen-Activated Protein Kinase (MAPK)–Dependent Pathway in Human Endometrial Cancer Cells,” PLoS ONE 8, no. 2 (2013): e55730.

[49] S. S. Kang, T. Kwon, D. Y. Kwon, and S. I. Do, “Akt Protein Kinase Enhances Human Telomerase Activity through Phosphorylation of Telomerase Reverse Transcriptase Subunit,” Journal of Biological Chemistry 274, no. 19 (1999): 13085–13090.

[50] J. Chung, P. Khadka, and I. K. Chung, “Nuclear Import of hTERT Requires a Bipartite Nuclear Localization Signal and Akt-Mediated Phosphorylation,” Journal of Cell Science 125, no. Pt 11 (2012): 2684–2697.

[51] T. Sundin, D. M. Peffley, and P. Hentosh, “Disruption of an hTERT–mTOR–RAPTOR Protein Complex by a Phytochemical Perillyl Alcohol and Rapamycin,” Molecular and Cellular Biochemistry 375, no. 1–2 (2013): 97–104.

[52] D. Pal, U. Sharma, S. K. Singh, N. Kakkar, and R. Prasad, “Inhibition of hTERT Expression by MAP Kinase Inhibitor Induces Cell Death in Renal Cell Carcinoma,” Urologic Oncology 35, no. 6 (2017): 401–408.

[53] R. Sears, F. Nuckolls, E. Haura, Y. Taya, K. Tamai, and J. R. Nevins, “Multiple Ras-Dependent Phosphorylation Pathways Regulate Myc Protein Stability,” Genes and Development 14, no. 19 (2000): 2501–2514.

[54] M. F. Bachmann and A. Oxenius, “Interleukin 2: From Immunostimulation to Immunoregulation and Back Again,” EMBO Reports 8, no. 12 (2007): 1142–1148.

[55] J. K. Sandberg, N. M. Fast, and D. F. Nixon, “Functional Heterogeneity of Cytokines and Cytolytic Effector Molecules in Human CD8+ T Lymphocytes,” Journal of Immunology 167, no. 1 (2001): 181–187.

[56] S. Ghaffari, M. Torabi-Rahvar, S. Aghayan, et al., “Optimizing Interleukin-2 Concentration, Seeding Density, and Bead-to-Cell Ratio of T-Cell Expansion for Adoptive Immunotherapy,” BMC Immunology 22, no. 1 (2021): 43.

[57] E. J. Grant and S. Gras, “Protocol for Generation of Human Peptide-Specific Primary CD8+ T Cell Lines,” STAR Protocols 3, no. 3 (2022): 101590.

[58] J. Jin, J. Lin, A. Xu, et al., “CCL2: An Important Mediator between Tumor Cells and Host Cells in Tumor Microenvironment,” Frontiers in Oncology 11 (2021): 722916.

[59] M. Xu, Y. Wang, R. Xia, Y. Wei, and X. Wei, “Role of the CCL2–CCR2 Signaling Axis in Cancer: Mechanisms and Therapeutic Targeting,” Cell Proliferation 54, no. 10 (2021): e13115.

[60] M. Liu, S. Guo, and J. K. Stiles, “The Emerging Role of CXCL10 in Cancer (Review),” Oncology Letters 2, no. 4 (2011): 583–589.

[61] R. Muthuswamy, J. M. Corman, K. Dahl, G. S. Chatta, and P. Kalinski, “Functional Reprogramming of Human Prostate Cancer to Promote Local Attraction of Effector CD8+ T Cells,” The Prostate 76, no. 12 (2016): 1095–1105.

[62] E. Mizukoshi and S. Kaneko, “Telomerase-Targeted Cancer Immunotherapy,” International Journal of Molecular Sciences 20, no. 8 (2019): 1823.

[63] K. Morgan, A. J. Stewart, N. Miller, et al., “Gonadotropin-Releasing Hormone Receptor Levels and Cell Context Affect Tumor Cell Responses to Agonist in Vitro and in Vivo,” Cancer Research 68, no. 15 (2008): 6331–6340.

[64] L. W. Cheung and A. S. Wong, “Gonadotropin-Releasing Hormone: GnRH Receptor Signaling in Extrapituitary Tissues,” FEBS Journal 275, no. 22 (2008): 5479–5495.

[65] P. Varamini, K. Dhiman, S. Khazeni, F. Mansfeld, and I. Toth, “Lipoamino Acid–Modified GnRH Analogs with Receptor-Mediated Antiproliferative Activity in Prostate and Ovarian Cancer Cells,” Medicinal Chemistry Research 30, no. 8 (2021): 1577–1585.

[66] Y. Tasdemiroglu, R. G. Gourdie, and J. Q. He, “In Vivo Degradation Forms, Anti-Degradation Strategies, and Clinical Applications of Therapeutic Peptides in Non-Infectious Chronic Diseases,” European Journal of Pharmacology 932 (2022): 175192.

[67] L. Wang, N. Wang, W. Zhang, et al., “Therapeutic Peptides: Current Applications and Future Directions,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 48.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.